肾移植后子痫前期:发生率及与移植物存活和功能的关系
该回顾性队列研究分析澳大利亚和新西兰透析与移植登记处2000至2021年肾移植后妊娠(≥20周)数据,子痫前期在357例妊娠中发生133例(37%),报告率从2000-2004年的27%升至2018-2021年的48%。子痫前期与移植物失败风险升高无关,而孕前肾功能是移植物存活的主要决定因素。
要点
- 肾移植后妊娠中子痫前期发生率为37%,报告率随年代上升。
- 子痫前期与死亡删失移植物失败风险升高无关。
- 孕前eGFR<45 ml/min/1.73 m²及孕前血肌酐≥1.24 mg/dl与移植物失败风险升高相关。
核心结论
- 在这个大型 contemporaneous 登记队列中,子痫前期与较差的移植物存活或功能无关,孕前肾功能是移植物存活的主要决定因素。
研究设计与样本
- 回顾性队列研究,分析澳大利亚和新西兰透析与移植登记处2000至2021年肾移植后妊娠(≥20周妊娠)数据。
- 子痫前期状态在390例妊娠中的357例中被捕获。
- 采用三个模型评估移植物存活,考虑重复妊娠和子痫前期发作。
主要发现
- 子痫前期发生在133例妊娠中(37%)。
- 报告的子痫前期妊娠百分比从2000-2004年的27%上升至2018-2021年的48%。
- 报告既往钙调神经磷酸酶抑制剂暴露总体较高,子痫前期女性更高(97% vs 88%,P=0.005)。
- 妊娠后识别出72例(27%)移植物失败,中位随访8.08年。
- 子痫前期女性孕前血清肌酐中位数更高(1.24 [IQR 1.00-1.50] vs 1.13 [0.99-1.36] mg/dl;P=0.02),但在所有生存模型中,子痫前期与更高的死亡删失移植物失败无关。
关键数值与推荐
- 在多变量分析中,仅年代和孕前血清肌酐浓度≥1.24 mg/dl(OR 2.48;95%CI 1.19-5.18)与更高的子痫前期风险相关。
- 孕前eGFR<45 ml/min/1.73 m²(调整HR 5.55;95%CI 3.27-9.44,P<0.001)和孕前血清肌酐≥1.24 mg/dl(调整HR 3.06;95%CI 1.77-5.27,P<0.001)与更高的移植物失败风险相关,即使在调整母亲特征后。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transplanted women have high rates of preeclampsia. However, determinants of preeclampsia and association with graft survival and function remain uncertain. We aimed to determine rates of preeclampsia and its association with kidney transplant survival and function. METHODS: This was a retrospective cohort study analyzing postkidney transplantation pregnancies (≥20 weeks gestation) from the Australia and New Zealand Dialysis and Transplant Registry (2000-2021). Graft survival was assessed in three models accounting for repeated pregnancies and episodes of preeclampsia. RESULTS: Preeclampsia status was captured in 357 of 390 pregnancies and occurred in 133 pregnancies (37%). The percentage of pregnancies reported to have preeclampsia rose from 27% in 2000-2004 to 48% from 2018 to 2021. Reported prior exposure to calcineurin inhibitors was high overall and higher in women who had preeclampsia (97% versus 88%, P = 0.005). Seventy-two (27%) graft failures were identified after a pregnancy, with a median follow-up of 8.08 years. Although women with preeclampsia had higher median preconception serum creatinine concentration (1.24 [interquartile range, 1.00-1.50] versus 1.13 [0.99-1.36] mg/dl; P = 0.02), in all survival models, preeclampsia was not associated with higher death-censored graft failure. In multivariable analysis of maternal factors (age, body mass index, primary kidney disease and transplant-pregnancy interval, preconception serum creatinine concentration, era of birth event, and tacrolimus or cyclosporin exposure), only era and preconception serum creatinine concentration ≥1.24 mg/dl (odds ratio, 2.48; 95% confidence interval [CI], 1.19 to 5.18) were associated with higher preeclampsia risk. Both preconception eGFR <45 ml/min per 1.73 m 2 (adjusted hazard ratio [HR], 5.55; 95% CI, 3.27 to 9.44, P < 0.001) and preconception serum creatinine concentration ≥1.24 mg/dl (adjusted HR, 3.06; 95% CI, 1.77 to 5.27, P < 0.001) were associated with a higher risk of graft failure even after adjusting for maternal characteristics. CONCLUSIONS: In this large and contemporaneous registry cohort, preeclampsia was not associated with worse graft survival or function. Preconception kidney function was the main determinant of graft survival.
引用
- Lu J, Hewawasam E, Davies CE, et al. Preeclampsia after Kidney Transplantation: Rates and Association with Graft Survival and Function. Clin J Am Soc Nephrol. 2023. PMID: 37099453. doi:10.2215/CJN.0000000000000155
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。